References
Smith ER, Cai MM, McMahon LP, Holt SG (2012) Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 97(9):3357–3365
Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234
Yamazaki Y, Okazaki R, Shibata M et al (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960
Braithwaite V, Bruggraber SF, Prentice A (2012) Intact fibroblast growth factor 23 and fragments in plasma from Gambian children. Osteoporosis Int. doi:10.1007/s00198-012-2029-3
Smith ER, Ford ML, Tomlinson LA, Weaving G, Rocks BF, Rajkumar C, Holt SG (2011) Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies. Clin Chim Acta 412:1008–1011
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
A reply to this comment is available at doi 10.1007/s00198-012-2251-z.
Rights and permissions
About this article
Cite this article
Smith, E.R., McMahon, L.P. & Holt, S.G. C-terminal FGF23 fragments: present but not seen?. Osteoporos Int 24, 1933–1934 (2013). https://doi.org/10.1007/s00198-012-2235-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-012-2235-z